Lophoras IP portfolio includes a composition of matter patent covering a wide area of chemical space encompassing millions of novel compounds within a novel compound class of phenethylamine derived psychedelics- granted in the US, Europe and elsewhere.
Furthermore, Lophora controls the rights to the proprietary manufacture of lead candidate LPH-5 and fast follower LPH-48, including protection of the novel salt and polymorphic form of both compounds.
Patent family “Selective 5-HT2A agonists”
International filing date: 6 November 2020. Expiry: 6 November 2040
- Europe (Granted 31 May 2023)
In force in Albania, Austria, Bosnia & Herzegovina, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Cambodia, Lithuania, Luxembourg, Latvia, Morocco, Monaco, Republic of Moldova, Montenegro, The Former Yugoslav Republic of Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Tunisia & Turkey
- Hong Kong
- Israel (Granted 3 July 2023)
- New Zealand
- South Africa (Granted 30 November 2022)
- US (Granted 15 February 2022)
- US divisional 1 (Granted 25 April 2023)
- US divisional 2 (Granted May 2023)
Patent family “Specific salts and polymorphs of 5-HT2A agonists”
International filing date: 5 May 2022. Expiry: 5 May 2042
Our patents have been developed in close collaboration with COPA Copenhagen Patents K/S.